Genfit Sa · EURONEXT:GNFT
Genfit Sa — Investor Presentation (September 2026)
18 slides from Genfit Sa's investor presentation, September 2026
Slide 1: Corporate presentation
Corporate presentation September 2026
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN INFORMATION CONTAINED IN THIS PRESENTATION CONCERNING ECONOMIC TRENDS AND PERFORMANCE HAS BEEN DERIVED FROM PUBLIC DISCLOSURES MADE
Slide 3: Corporate Highlights
Corporate Highlights Partnership with Ipsen French biopharmaceutical company ► PBC: Iqirvo® launched in 20241,2 Listed on EURONEXT “GNFT” ▪ Upfront of €120M ▪ 8% equity stake 25+ years in liver diseases, taking ▪ Up to €360M milestones (€105.5M received, potential early assets to commercial stage1 €
Slide 4: Solid Commercial Performance from Ipsen in PBC
1. Elafibranor Solid Commercial Performance from Ipsen in PBC Iqirvo® sales (global, quarterly) since commercial launch1 400 350 94.4 300 Cumulative milestone payments received to date2 Global sales (millions of euros) 250 78.8 €105.5M 200 Cumulative royalties received to date3 76.6 150 283,4 €34M 1
Slide 5: ELATIVE Ph3 Results and Ipsen's Updated Iqirvo Peak Sales Guidance in PBC
ELATIVE Ph3 Results and Ipsen’s Updated Iqirvo® Peak Sales Guidance in PBC July 13, 2026 Upgraded Iqirvo peak sales of €1bn in PBC Source: Ipsen public disclosures. Commercial information has been derived from publicly available information released by Ipsen. GENFIT has not independently verified su
Slide 6: Ongoing Phase 3 Trial by Ipsen in PSC
Ongoing Phase 3 Trial by Ipsen in PSC Source: Ipsen’s 2025 Full-Year Results In February 2026, Ipsen confirmed the initiation of the first and only global Phase 3 clinical trial, addressing a significant unmet medical need, as no approved therapies currently exist for this severe and progressive dis
Slide 7: Non-Invasive Diagnosis of MASH Utilizing GENFIT's Technology
2. MASH Non-Invasive Diagnosis of MASH Utilizing GENFIT’s Technology Patient identification landscape Labcorp’s NASHnext LDT test available to millions of patients NASHnext® will be reimbursed by Medicare under Adults expected to present the Clinical Laboratory Fee Schedule. risk factors for Reimbur
Slide 8: GENFIT's Technology Recognized by Leading Consortia, Guidelines and Industry Sponsors
GENFIT’s Technology Recognized by Leading Consortia, Guidelines and Industry Sponsors LITMUS consortium (Europe) NIMBLE consortium (U.S.) Topline results from NIMBLE consortium, stage 1 (N=1073)2 MASH At-risk MASH F stage ≥2 AUROC (95% CI) p (vs ALT) AUROC (95% CI) p (vs ALT) AUROC (95% CI) p (vs FI
Slide 9: A Decade of Vision and Execution Advancing Toward Large-Scale Adoption
A Decade of Vision and Execution Advancing Toward Large-Scale Adoption DIAGNOSTIC Two historically Strategic groundwork Key steps toward complementary programs and pre-positioning large-scale adoption + MONITORING Therapeutic program (elafibranor in MASH1) 2015 2020 2026 2028 Diagnostic program (NIS
Slide 10: CCA with KRAS Mutation: A High Unmet Medical Need
3. CCA CCA with KRAS Mutation: A High Unmet Medical Need Rare and aggressive liver malignancy ~30% of patients with CCA harbor KRAS mutations4 that develops in the bile ducts • one of the most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways5
Slide 11: Rationale for Combining Anticancer Therapies and GNS561
Rationale for Combining Anticancer Therapies and investigational drug GNS561, an Autophagy Inhibitor GNS561 PPT1 inhibitor in #1 Anticancer Therapies combination with #2 GNS561 a MEK inhibitor Oral (Autophagy inhibitor) Chemotherapeutic agents MAP Kinase pathway targeted therapies By entering the ly
Slide 12: Phase 1b GNS561+MEKi: Highly Encouraging Early Data
Phase 1b GNS561+MEKi: Highly Encouraging Early Data Advanced KRAS-mutated cholangiocarcinoma remains an area of high unmet medical need, particularly in patients who have progressed after prior therapies. What is notable in these data is the consistency of the signal as additional patients have been
Slide 13: Additional Opportunities with GNS561 in Oncology
Additional Opportunities with GNS561 in Oncology Beyond CCA: a potential to explore the benefit of autophagy inhibition in other cancers The number of publications implicating autophagy Rationale to expand GNS561 program into GI/liver tumors where: in cancer treatment resistance has increased by ✓ A
Slide 14: ACLF: A High Unmet Medical Need
4. ACLF ACLF: A High Unmet Medical Need CHRONIC PHASE ACUTE PHASE Acute Chronic Liver Disease Cirrhosis ACLF 23-74% mortality at 28 days Decompensation = UNDERLYING CONDITION = PRECIPITANT ≥ 1 ORGAN DYSFUNCTIONS/FAILURES ► NO APPROVED DRUGS Bacterial Alcohol Alcohol Viruses Kidney Cerebral Infection
Slide 15: A Strong Scientific Rationale for Our Lead Asset G1090N/NTZ
A Strong Scientific Rationale for Our Lead Asset G1090N/NTZ Findings to date: G1090N/NTZ ✓ Decreases systemic inflammation in animal models, including in ACLF models ✓ Protects liver, kidney & brain in rat models of ACLF by decreasing tissue damage Anti-inflammatory Oral ✓ Protects mice from mortali
Slide 16: G1090N/NTZ's Potential Recently Confirmed in the Clinic
G1090N/NTZ’s Potential Recently Confirmed in the Clinic G1090N/NTZ Anti-inflammatory Oral The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for
Slide 17: Other R&D Programs
5. Other Other R&D Programs ACLF Continuum UCD/OA Research Collaboration with EVerZom1 SRT-015 CLM-022 VS-02-HE EViv VS-01-HAC Injectable Oral Injectable Peritoneal ASK1 NLRP3 inflammasome Urease Exosome Liposomal-based inhibitor inhibitor inhibitor Technology technology To inhibit apoptosis, To inh
Slide 18: Targeting Untapped Markets with High Potential
Potential Targeting Untapped Markets with High Potential ACLF 294,000 in 2021, US, EU4, UK | ~300,000 by 2036 ~$4Bn for grade 1-2 ACLF in US, EU4, UK by 2030 CCA 20,000 to 30,000 for US, EU4, UK ~$3.1Bn for US, EU4, UK UCD/OA 2,000 to 3,000 for US, EU4, UK ~$1.1Bn for US, EU4, UK PBC ~385,000 for Gl